ArticleNature immunology2024
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells.
Open access · hybridAbstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
9.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 41 citations in OpenAlex.
- In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles.Nature biotechnology · 2026Article
- Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy.Nature immunology · 2026Article
- HIV-1 Env Heterogeneity: Cleavage, Trafficking, and Antigenic Consequences for Virions and Infected Cells.Viruses · 2026Review
- HIV cure after HCT: 7 horses seem to be on the mark.Blood advances · 2026Article
- Opportunities and challenges in achieving a functional cure for HIV.Infectious diseases & immunity · 2026Review
- Article
- Advancement of humanized mice and leading applications in immunological disease models.Inflammation and regeneration · 2026Review
- Article
- Persistent immune dysfunction during suppressive antiretroviral therapy: implications for analytical treatment interruption trials for chronic HIV infections in sub-Saharan Africa.Frontiers in immunology · 2026Review
- Beyond monotherapy: Combination therapies for HIV-1 cure through joint application of neutralizing antibodies, genome editing, and reservoir management.Infectious medicine · 2025Review
- Virus envelope glycoprotein targeting bispecific T cell engager protects mice from lethal severe fever with thrombocytopenia virus infection.Cell reports. Medicine · 2025Article
- Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance.Current opinion in HIV and AIDS · 2025Review
- Engineering HIV antibodies with enhanced breadth and potency of neutralization through multistate affinity maturation.bioRxiv : the preprint server for biology · 2025Article
- Engineering Bispecific Peptides for Precision Immunotherapy and Beyond.International journal of molecular sciences · 2025Review
- A TCR-mimic bispecific antibody reduces HIV-1 provirus and delays viral rebound in HLA-matched humanized mice.bioRxiv : the preprint server for biology · 2025Article
- A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV.Structure (London, England : 1993) · 2025Article
- Article
- Inhibition of ALKBH5 demethylase of mVirology journal · 2025Article
- Yoda1, a Piezo1 agonist, induced latent HIV reactivation associated with upregulation of CD3/TCR complex and HLA genes.Research square · 2025Article
- A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Nathan L Board *Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-5208-9970
Zhe Yuan *The Wistar Institute, Philadelphia, PA, USA.
Fengting WuDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Milica MoskovljevicDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-0436-6854
Meghana RaviDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Srona SenguptaDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sung Soo MunDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-3735-6057
Francesco R SimonettiDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4165-660X
Jun LaiDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pablo TebasPresbyterian Hospital-University of Pennsylvania Hospital, Philadelphia, PA, USA.
Kenneth LynnPresbyterian Hospital-University of Pennsylvania Hospital, Philadelphia, PA, USA.
Rebecca HohDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Steven G DeeksDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Janet D SilicianoDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. jsilicia@jhmi.edu.ORCID http://orcid.org/0000-0001-6712-3775
Luis J MontanerThe Wistar Institute, Philadelphia, PA, USA. montaner@wistar.org.ORCID http://orcid.org/0000-0001-5799-6759
Robert F SilicianoDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. rsiliciano@jhmi.edu.ORCID http://orcid.org/0000-0002-1764-1993
Johns Hopkins University · USPennsylvania Hospital · USThe Wistar Institute · USUniversity of California, San Francisco · USHoward Hughes Medical Institute · US
Funding
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0MBEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7MDelaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0MI4C 2.0: Immunotherapy for CureUM1AI164556 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch, John W Mellors · 2021 to 2026
$28.0MInvestigating antigen-driven clonal proliferation to target HIV-1 persistenceDP5OD031834 · OD · JOHNS HOPKINS UNIVERSITY · PI SIMONETTI, FRANCESCO ROBERTO · 2021 to 2025
$2.0MNIAID NIH HHS P30 AI094189NIAID NIH HHS UM1 AI164556NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164570NIH HHS DP5 OD031834
Abstract
The persistence of CD4
Indexed as
Antibodies, BispecificHIV-1AnimalsCell DeathCytotoxicity, ImmunologicHumansKiller Cells, NaturalMiceMice, TransgenicAntibodies, Bispecific
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.